m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05745
 [1]
m6A modification miR-27a-3p miR-27a-3p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-27a-3p PPARG  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-27a-3p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-27a-3p microRNA View Details
Regulated Target Peroxisome proliferator-activated receptor gamma (PPARG) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary OMT exhibited a dose-dependent inhibitory effect on the volume of IH PPNL-resistant tumors, which was partially dependent on the regulation of m6A methylation transfer enzyme METTL3 and the hsa-miR-27a-3p/Peroxisome proliferator-activated receptor gamma (PPARG) axis, thereby inducing apoptosis.
Responsed Disease Infantile hemangioma ICD-11: 2E81
 Disease Info 
Responsed Drug Oxymatrine
 Drug Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell apoptosis
In-vitro Model
 HemSCs/PPNL (Propranolol (PPNL)-resistant hemangioma stem cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Peroxisome proliferator-activated receptor gamma (PPARG) 143 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Pioglitazone Approved [2]
Synonyms
111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
    Click to Show/Hide
MOA Agonist
External Link
CID: 4829
TTD: D03OFF
DrugBank: DB01132
 Compound Name Troglitazone Approved [3]
Synonyms
Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
    Click to Show/Hide
MOA Agonist
External Link
CID: 5591
TTD: D06XZW
DrugBank: DB00197
 Compound Name Rosiglitazone XR Approved [4]
Synonyms
Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
    Click to Show/Hide
MOA Agonist
Activity Ki = 14 nM
External Link
CID: 5281055
TTD: D0K5ER
 Compound Name Thiazolidinedione Approved [2]
Synonyms
2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487
    Click to Show/Hide
MOA Agonist
External Link
CID: 5437
TTD: D0K8IX
DrugBank: DB11898
 Compound Name Lobeglitazone Approved [5]
Synonyms
Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang
    Click to Show/Hide
MOA Agonist
External Link
CID: 9826451
TTD: D04BCB
DrugBank: DB09198
 Compound Name Glitazone Phase 4 [6]
Synonyms
74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087
    Click to Show/Hide
MOA Agonist
External Link
CID: 10198397
TTD: D0S2BV
 Compound Name Rivoglitazone Phase 3 [7]
Synonyms
CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
    Click to Show/Hide
MOA Agonist
Activity EC50 = 43 nM
External Link
CID: 3055168
TTD: D08PFA
DrugBank: DB09200
 Compound Name Balaglitazone Phase 3 [8]
Synonyms
DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
    Click to Show/Hide
MOA Modulator
External Link
CID: 9889200
TTD: D0F3NH
DrugBank: DB12781
 Compound Name FARGLITAZAR Phase 3 [9]
Synonyms
GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-
    Click to Show/Hide
MOA Modulator
Activity EC50 = 0.3388 nM
External Link
CID: 170364
TTD: D0M0SS
 Compound Name Rosiglitazone + simvastatin Phase 3 [4]
MOA Agonist
External Link
CID: 23644561
TTD: D0Q6IW
 Compound Name Leriglitazone Phase 3 [10]
Synonyms
146062-44-4; 1-Hydroxypioglitazone; 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; A1-01710; AKOS015856344; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE; BDBM50530214; CHEBI:82937; CHEMBL1267; CS-0067030; D11603; DB15021; DTXSID30399914; FT-0643388; HY-117727; Hydroxy Pioglitazone (M-IV); Hydroxy Pioglitazone-D5 (Major) (M-IV); Hydroxypioglitazone; J-008187; K824X25AYA; Leriglitazone; Leriglitazone (USAN/INN); LERIGLITAZONE [INN]; Leriglitazone [USAN]; MIN-102; OXVFDZYQLGRLCD-UHFFFAOYSA-N; Pioglitazone, hydroxy; Q27156475; SCHEMBL4098326; UNII-K824X25AYA; WHO 10868; ZINC01482947
    Click to Show/Hide
MOA Agonist
External Link
CID: 4147757
TTD: DCA13V
DrugBank: DB15021
 Compound Name Ragaglitazar Phase 3 [11]
Synonyms
DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid
    Click to Show/Hide
MOA Modulator
Activity Ki = 90 nM
External Link
CID: 447458
TTD: D02NHD
DrugBank: DB07675
 Compound Name CS-038 Phase 3 [12]
Synonyms
Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences
    Click to Show/Hide
MOA Modulator
External Link
CID: 71402018
TTD: D0F5JH
 Compound Name TESAGLITAZAR Phase 3 [13]
Synonyms
251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
    Click to Show/Hide
MOA Modulator
Activity EC50 = 13 nM
External Link
CID: 208901
TTD: D0H1NL
DrugBank: DB07399
 Compound Name MURAGLITAZAR Phase 3 [14]
Synonyms
331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N
    Click to Show/Hide
MOA Modulator
Activity EC50 = 3 nM
External Link
CID: 206044
TTD: D0M3UT
DrugBank: DB06510
 Compound Name ZYH-1 Phase 3 [15]
Synonyms
Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0T7MN
 Compound Name Imiglitazar Phase 3 [16]
Synonyms
TAK-559
    Click to Show/Hide
MOA Modulator
Activity EC50 = 4 nM
External Link
CID: 9890879
TTD: D0VU5M
DrugBank: DB12511
 Compound Name Rosiglitazone + metformin Phase 3 [4]
Synonyms
Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]
    Click to Show/Hide
MOA Agonist
External Link
CID: 5329099
TTD: D0A1AQ
DrugBank: DB12072
 Compound Name MBX-102 Phase 2/3 [17]
Synonyms
Arhalofenate; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV
    Click to Show/Hide
MOA Agonist
Activity EC50 > 500 nM
External Link
CID: 12082259
TTD: D0X7VB
DrugBank: DB11811
 Compound Name FK-614 Phase 2 [18]
Synonyms
ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus
    Click to Show/Hide
MOA Agonist
Activity EC50 = 163 nM
External Link
CID: 9869229
TTD: D00PJJ
DrugBank: DB12557
 Compound Name Netoglitazone Phase 2 [19]
Synonyms
Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
    Click to Show/Hide
MOA Modulator
External Link
CID: 204109
TTD: D02TGD
DrugBank: DB09199
 Compound Name MBX-2044 Phase 2 [17]
Synonyms
MBX-102 analogs, Metabolex
    Click to Show/Hide
MOA Agonist
External Link
TTD: D08NPG
 Compound Name GED-0507-34-Levo Phase 2 [20]
Synonyms
GED-0507; GED-0507-34; GED-0507-34E2
    Click to Show/Hide
MOA Agonist
External Link
CID: 67008033
TTD: D0E6ME
 Compound Name CHS-131 Phase 2 [21]
MOA Modulator
External Link
TTD: D0P5SU
 Compound Name OMS405 Phase 2 [22]
MOA Agonist
External Link
TTD: D0W0JP
 Compound Name Naveglitazar Phase 2 [23]
Synonyms
LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand
    Click to Show/Hide
MOA Modulator
Activity IC50 = 33.96 nM
External Link
CID: 9888484
TTD: D04BPS
DrugBank: DB12662
 Compound Name ONO-5129 Phase 2 [24]
Synonyms
Dual PPAR alpha/gamma agonist (metabolic disorder), Ono
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0PP8G
 Compound Name T3D-959 Phase 2 [25]
MOA Agonist
External Link
TTD: D53BEH
 Compound Name T3D-959 Phase 1/2 [26]
MOA Modulator
External Link
TTD: D0ZT8A
 Compound Name CLX-0921 Phase 1 [27]
Synonyms
CLX-090502; CLX-090503; CLX-090717; CLX-092402
    Click to Show/Hide
MOA Agonist
External Link
CID: 9958278
TTD: D06TWE
 Compound Name DSP-8658 Phase 1 [28]
MOA Modulator
External Link
TTD: D07IGC
 Compound Name Englitazone sodium Phase 1 [29]
Synonyms
Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt
    Click to Show/Hide
MOA Agonist
External Link
CID: 13728795
TTD: D08EEU
 Compound Name Oxeglitazar Phase 1 [30]
Synonyms
EMD-336340; EML-16156; EML-4156; LM-4156
    Click to Show/Hide
MOA Modulator
External Link
CID: 6445229
TTD: D03RJZ
 Compound Name GW-409544 Phase 1 [31]
Synonyms
GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo
    Click to Show/Hide
MOA Modulator
Activity EC50 = 0.2 nM
External Link
CID: 446642
TTD: D0AX9S
 Compound Name Spirolaxine derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-L
    Click to Show/Hide
MOA Agonist
External Link
TTD: D03GFB
 Compound Name Phenylpropionic acid derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-D
    Click to Show/Hide
MOA Agonist
External Link
TTD: D09OXG
 Compound Name A-substituted phenylpropionic acid derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-c
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0E9GF
 Compound Name PMID25416646-Compound-Figure2-K Patented [32]
MOA Agonist
External Link
CID: 10229498
TTD: D0G3KY
DrugBank: DB05490
 Compound Name PMID25416646-Compound-Figure2-N Patented [32]
MOA Agonist
External Link
TTD: D0GG5K
 Compound Name MRL24 Patented [32]
Synonyms
MRL 24
    Click to Show/Hide
MOA Agonist
Activity EC50 = 1 nM
External Link
CID: 9958543
TTD: D0H5FI
 Compound Name Sulfonamide derivative 18 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-M
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0HT9C
 Compound Name Crystalline anhydrous toluene derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-H
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0M4RD
 Compound Name A-substituted phenylpropionic acid derivative 2 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-E
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0M5YQ
 Compound Name Biaromatic compound 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-A
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0O8PR
 Compound Name MRL20 Patented [32]
Synonyms
CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid
    Click to Show/Hide
MOA Agonist
Activity EC50 = 2 nM
External Link
CID: 10143056
TTD: D0PO7F
 Compound Name Fused ring compound 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-G
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0SL0K
 Compound Name 3-phenyl acrylic acid derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-B
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0SV6U
 Compound Name Thiazolidine dione crystalline derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-I
    Click to Show/Hide
MOA Agonist
External Link
CID: 9832447
TTD: D0TF0T
DrugBank: DB11894
 Compound Name Fused aromatic compound 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure2-F
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0UG1W
 Compound Name PMID25416646-Compound-Figure2-J Patented [32]
MOA Agonist
External Link
TTD: D0UH5B
 Compound Name Cannabinoid quinone derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure3-A
    Click to Show/Hide
MOA Ligand
External Link
TTD: D0ZO0D
 Compound Name PMID25416646-Compound-Figure5-H Patented [32]
MOA Agonist
External Link
TTD: D05AUY
 Compound Name Flavonoid derivative 8 Patented [32]
Synonyms
PMID25416646-Compound-Figure5-B
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0HW6Y
 Compound Name PMID25416646-Compound-Figure5-E Patented [32]
MOA Agonist
External Link
TTD: D0LA6O
 Compound Name Phenylpyridine derivative 3 Patented [32]
Synonyms
PMID25416646-Compound-Figure5-G
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0NF8V
 Compound Name PMID25416646-Compound-Figure5-A Patented [32]
MOA Agonist
External Link
TTD: D0O5IN
 Compound Name 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 Patented [32]
Synonyms
PMID25416646-Compound-Figure5-F
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0U6AW
 Compound Name PMID25416646-Compound-Figure5-C Patented [32]
MOA Agonist
External Link
TTD: D0V0JN
 Compound Name YM-440 Discontinued in Phase 2 [33]
Synonyms
2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9890786
TTD: D0KL3K
 Compound Name KRP-297 Discontinued in Phase 2 [34]
Synonyms
MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384
    Click to Show/Hide
MOA Modulator
External Link
CID: 151183
TTD: D02RAU
 Compound Name Reglixane Discontinued in Phase 2 [24]
MOA Modulator
External Link
TTD: D02ZKL
 Compound Name AVE-0847 Discontinued in Phase 2 [35]
Synonyms
PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0W2IU
 Compound Name Sodelglitazar Discontinued in Phase 2 [36]
Synonyms
447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac
    Click to Show/Hide
MOA Agonist
External Link
CID: 9805950
TTD: D01JGG
 Compound Name Indeglitazar Discontinued in Phase 2 [37]
Synonyms
PLX-204
    Click to Show/Hide
MOA Agonist
External Link
CID: 11395145
TTD: D09OHP
DrugBank: DB07724
 Compound Name GSK-677954 Discontinued in Phase 2 [38]
Synonyms
SCHEMBL2065429
    Click to Show/Hide
MOA Agonist
External Link
CID: 56603715
TTD: D0S6KX
 Compound Name DS-6930 Discontinued in Phase 1 [39]
MOA Modulator
External Link
TTD: D0Z6OI
 Compound Name E-3030 Discontinued in Phase 1 [40]
Synonyms
Dual PPAR alpha/gamma agonists, Eisai
    Click to Show/Hide
MOA Modulator
External Link
CID: 11949481
TTD: D06PHO
 Compound Name LY-929 Discontinued in Phase 1 [41]
Synonyms
LY-510929; Dual PPAR-alpha/PPAR-gamma agonists
    Click to Show/Hide
MOA Agonist
Activity EC50 = 3.981 nM
External Link
CID: 9890585
TTD: D0B0EB
 Compound Name Ciglitazone Preclinical [42]
Synonyms
74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01
    Click to Show/Hide
MOA Agonist
External Link
CID: 2750
TTD: D03GWY
DrugBank: DB09201
 Compound Name MC-3002 Preclinical [24]
Synonyms
PPAR dual agonists, MaxoCore
    Click to Show/Hide
MOA Modulator
External Link
TTD: D08WOE
 Compound Name SB-219994 Terminated [43]
Synonyms
SB-219993
    Click to Show/Hide
MOA Agonist
Activity EC50 = 1 nM
External Link
CID: 9845965
TTD: D00YGA
 Compound Name AKP-320 Terminated [44]
Synonyms
Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis
    Click to Show/Hide
MOA Modulator
External Link
TTD: D04JVX
 Compound Name Edaglitazone Terminated [45]
Synonyms
Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602
    Click to Show/Hide
MOA Modulator
External Link
CID: 9825701
TTD: D08VKZ
DrugBank: DB06519
 Compound Name DARGLITAZONE Terminated [46]
Synonyms
CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
MOA Agonist
External Link
CID: 60870
TTD: D0N1EF
DrugBank: DB14034
 Compound Name BVT-142 Terminated [47]
Synonyms
BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0I0RF
 Compound Name AD-5075 Terminated [48]
Synonyms
2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075
    Click to Show/Hide
MOA Modulator
External Link
CID: 128440
TTD: D0LB4T
 Compound Name Sipoglitazar Terminated [15]
Synonyms
TAK-654
    Click to Show/Hide
MOA Modulator
External Link
CID: 9825652
TTD: D0OW6Z
 Compound Name CS-204 Terminated [49]
Synonyms
CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0V0TT
 Compound Name 15-deoxy-Delta(12, 14)-prostaglandin J(2) Investigative [3]
Synonyms
15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2
    Click to Show/Hide
MOA Agonist
External Link
CID: 5311211
TTD: D01PGU
 Compound Name (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid Investigative [50]
Synonyms
LT175; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 480 nM
External Link
CID: 11483970
TTD: D06MDX
DrugBank: DB08121
 Compound Name 3-(5-methoxy-1H-indol-3-yl)propanoic acid Investigative [50]
Synonyms
39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 181137
TTD: D0E5HC
DrugBank: DB07723
 Compound Name (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid Investigative [50]
Synonyms
CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 3600 nM
External Link
CID: 11149906
TTD: D0H4US
DrugBank: DB07842
 Compound Name (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Investigative [50]
Synonyms
CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 2691.53 nM
External Link
CID: 11460087
TTD: D0J3UU
DrugBank: DB08760
 Compound Name GW7845 Investigative [51]
Synonyms
GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)
    Click to Show/Hide
MOA Agonist
Activity EC50 = 0.6166 nM
External Link
CID: 9870584
TTD: D0O2US
 Compound Name (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid Investigative [50]
Synonyms
13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6443013
TTD: D0Z5TV
DrugBank: DB06926
 Compound Name GW-2331 Investigative [52]
Synonyms
190844-95-2; PPAR ligand, Glaxo Wellcome
    Click to Show/Hide
MOA Modulator
Activity EC50 = 243 nM
External Link
CID: 657048
TTD: D01POG
 Compound Name 9-hydroxyoctadecadienoic acid Investigative [50]
Synonyms
(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5312830
TTD: D0SZ4T
DrugBank: DB07302
 Compound Name ZY H2 Investigative [53]
Synonyms
ZYH2
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0Z4MH
 Compound Name 2-chloro-5-nitro-N-phenylbenzamide Investigative [50]
Synonyms
GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 2 nM
External Link
CID: 644213
TTD: D00ACX
DrugBank: DB07863
 Compound Name DB-900 Investigative [54]
MOA Agonist
External Link
TTD: D01ARG
 Compound Name Bardoxolone methyl Phase 3 [55]
Synonyms
BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4
    Click to Show/Hide
External Link
CID: 400769
TTD: D0JU5X
DrugBank: DB05983
 Compound Name AD-5075 Terminated [48]
Synonyms
2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075
    Click to Show/Hide
MOA Modulator
External Link
CID: 128440
TTD: D0LB4T
 Compound Name (E)-9-nitrooctadec-9-enoic acid Investigative [55]
Synonyms
9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid
    Click to Show/Hide
Activity IC50 = 980 nM
External Link
CID: 11645581
TTD: D01RPM
 Compound Name tagitinin A Investigative [55]
Synonyms
59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01
    Click to Show/Hide
Activity IC50 = 55000 nM
External Link
CID: 181254
TTD: D01UVA
 Compound Name T0070907 Investigative [55]
Synonyms
2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21
    Click to Show/Hide
Activity IC50 = 1000 nM
External Link
CID: 2777391
TTD: D03BPG
 Compound Name GW1929 Investigative [55]
Synonyms
GW 1929; GW-1929
    Click to Show/Hide
Activity Ki = 0.0497 nM
External Link
CID: 6518171
TTD: D04DYM
 Compound Name (E)-9-Nitrohexadec-9-enoicAcid Investigative [55]
Synonyms
CHEMBL560513; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047
    Click to Show/Hide
Activity IC50 = 830 nM
External Link
CID: 44220886
TTD: D04FVX
 Compound Name (E)-10-nitrooctadec-9-enoic acid Investigative [55]
Synonyms
10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N
    Click to Show/Hide
Activity IC50 = 1610 nM
External Link
CID: 24836820
TTD: D06IHG
DrugBank: DB15026
 Compound Name SB-213068 Investigative [55]
Synonyms
CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)
    Click to Show/Hide
Activity Ki = 2.5 nM
External Link
CID: 9843045
TTD: D06NHI
 Compound Name tirotundin Investigative [55]
Synonyms
56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657
    Click to Show/Hide
Activity IC50 = 27000 nM
External Link
CID: 9975297
TTD: D06OBX
 Compound Name L-Tryptophan-L-aspartic acid Investigative [55]
Synonyms
H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632
    Click to Show/Hide
Activity IC50 = 5200 nM
External Link
CID: 7019108
TTD: D06UVY
 Compound Name BRL-48482 Investigative [55]
Synonyms
SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9822139
TTD: D07IHY
 Compound Name nTzDpa Investigative [55]
Synonyms
118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3
    Click to Show/Hide
Activity IC50 = 26 nM
External Link
CID: 9954280
TTD: D08QKF
 Compound Name COOH Investigative [55]
Synonyms
LS-191838
    Click to Show/Hide
External Link
CID: 10025649
TTD: D0A1SP
 Compound Name ISIS 105990 Investigative [55]
External Link
TTD: D0B2UF
 Compound Name ISIS 106008 Investigative [55]
External Link
TTD: D0B9MZ
 Compound Name CHLOROCYCLINONE A Investigative [55]
Synonyms
CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
    Click to Show/Hide
Activity IC50 = 160 nM
External Link
CID: 24762579
TTD: D0D0FQ
 Compound Name ISIS 105987 Investigative [55]
External Link
TTD: D0G3IV
 Compound Name L-Tryptophan-L-glutamine Investigative [55]
Synonyms
CHEMBL476173; SCHEMBL5970454
    Click to Show/Hide
Activity IC50 = 18700 nM
External Link
CID: 25187914
TTD: D0G9AI
 Compound Name PAT5A Investigative [55]
Synonyms
GTPL2709
    Click to Show/Hide
External Link
CID: 18980163
TTD: D0HI6O
 Compound Name GNF-PF-2893 Investigative [55]
Synonyms
MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea
    Click to Show/Hide
External Link
CID: 2815701
TTD: D0I2DF
 Compound Name L-Tryptophan-L-asparagine Investigative [55]
Synonyms
CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid
    Click to Show/Hide
Activity IC50 = 18400 nM
External Link
CID: 7020170
TTD: D0IW8V
 Compound Name L-Tryptophan-L-2-aminoadipic acid Investigative [55]
Synonyms
CHEMBL515773
    Click to Show/Hide
Activity IC50 = 15100 nM
External Link
CID: 25185696
TTD: D0J9ZA
 Compound Name L-764406 Investigative [55]
Synonyms
L 764406; L764406
    Click to Show/Hide
External Link
CID: 9818466
TTD: D0L4PT
 Compound Name L-Tryptophan-L-arginine Investigative [55]
Synonyms
CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH inverted exclamation mark currency 2 HCl
    Click to Show/Hide
Activity IC50 = 15400 nM
External Link
CID: 25186251
TTD: D0M7AT
 Compound Name ISIS 105989 Investigative [55]
External Link
TTD: D0NW8N
 Compound Name [125I]SB-236636 Investigative [55]
Synonyms
GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid
    Click to Show/Hide
External Link
CID: 73755028
TTD: D0P1US
 Compound Name BADGE Investigative [55]
Synonyms
SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane
    Click to Show/Hide
Activity IC50 = 100000 nM
External Link
CID: 2286
TTD: D0Q4EU
DrugBank: DB14083
 Compound Name (E)-5-Nitrooctadec-5-enoic Acid Investigative [55]
Synonyms
CHEMBL561776; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050
    Click to Show/Hide
Activity IC50 = 1680 nM
External Link
CID: 44220888
TTD: D0Q4UD
 Compound Name CHLOROCYCLINONE C Investigative [55]
Synonyms
CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
    Click to Show/Hide
Activity EC50 = 130 nM
External Link
CID: 24180661
TTD: D0R9VV
 Compound Name CHLOROCYCLINONE B Investigative [55]
Synonyms
CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
    Click to Show/Hide
Activity EC50 = 160 nM
External Link
CID: 24762580
TTD: D0RL8P
 Compound Name GW0072 Investigative [55]
Synonyms
GW 0072
    Click to Show/Hide
External Link
CID: 449532
TTD: D0SO9Q
 Compound Name [3H]GW2331 Investigative [55]
Synonyms
GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
    Click to Show/Hide
External Link
CID: 10624977
TTD: D0T8JM
 Compound Name CHLOROCYCLINONE D Investigative [55]
Synonyms
CHEMBL400132; BDBM50228361
    Click to Show/Hide
Activity EC50 = 260 nM
External Link
CID: 24762578
TTD: D0U5HX
 Compound Name (E)-10-Nitrohexadec-9-enoic Acid Investigative [55]
Synonyms
CHEMBL564368; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N
    Click to Show/Hide
Activity IC50 = 630 nM
External Link
CID: 44220887
TTD: D0W9WU
 Compound Name L-Tryptophan-L-leucine Investigative [55]
Synonyms
H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
    Click to Show/Hide
Activity IC50 = 25800 nM
External Link
CID: 6997510
TTD: D0X3RZ
 Compound Name PD-068235 Investigative [55]
Synonyms
CHEMBL455856; BDBM50266362; PD-068253
    Click to Show/Hide
Activity IC50 = 820 nM
External Link
CID: 44581800
TTD: D0X9UJ
 Compound Name Ploglitazone Investigative [55]
External Link
CID: 12944192
TTD: D0Z2CY
 Compound Name (E)-6-Nitrooctadec-5-enoic Acid Investigative [55]
Synonyms
CHEMBL569372
    Click to Show/Hide
Activity IC50 = 1720 nM
External Link
CID: 44220889
TTD: D0Z4NW
 Compound Name AD-5061 Investigative [55]
Synonyms
AD-7057; AD7057; AD 7057; AD5061; AD 5061
    Click to Show/Hide
External Link
CID: 9953271
TTD: D00EOP
 Compound Name TZD18 Investigative [55]
Synonyms
TZD 18; TZD-18
    Click to Show/Hide
External Link
CID: 9827261
TTD: D04JOG
 Compound Name (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid Investigative [55]
Synonyms
12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid
    Click to Show/Hide
Activity EC50 = 45 nM
External Link
CID: 5282316
TTD: D06GYO
 Compound Name reglitazar Investigative [55]
Synonyms
JTT-501
    Click to Show/Hide
External Link
CID: 154000
TTD: D08XGH
DrugBank: DB04971
 Compound Name DRF 2519 Investigative [55]
Synonyms
5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2
    Click to Show/Hide
External Link
CID: 9908833
TTD: D0M8VN
 Compound Name (E)-12-Nitrooctadec-12-enoic Acid Investigative [55]
Synonyms
CHEMBL549351; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid
    Click to Show/Hide
Activity IC50 = 39 nM
External Link
CID: 44221100
TTD: D0M9LL
 Compound Name (E)-13-Nitrooctadec-12-enoic Acid Investigative [55]
Synonyms
CHEMBL540732
    Click to Show/Hide
Activity IC50 = 190 nM
External Link
CID: 44221101
TTD: D0P5QM
 Compound Name GNF-PF-3037 Investigative [55]
Synonyms
SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide
    Click to Show/Hide
External Link
CID: 1160447
TTD: D0P8XE
 Compound Name LY-465608 Investigative [55]
Synonyms
LY465608; LY 465608
    Click to Show/Hide
Activity IC50 = 548 nM
External Link
CID: 9890319
TTD: D0Z7OX
 Compound Name 2-chloro-5-nitro-N-phenylbenzamide Investigative [50]
Synonyms
GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 2 nM
External Link
CID: 644213
TTD: D00ACX
DrugBank: DB07863
 Compound Name L-796449 Investigative [55]
Synonyms
UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
    Click to Show/Hide
Activity EC50 = 5.2 nM
External Link
CID: 9891946
TTD: D09JII
 Compound Name L-165461 Investigative [55]
Synonyms
CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
    Click to Show/Hide
Activity EC50 = 19 nM
External Link
CID: 9889841
TTD: D0F0MP
 Compound Name L-783483 Investigative [55]
Synonyms
F3MethylAA
    Click to Show/Hide
Activity EC50 = 23 nM
External Link
CID: 9935197
TTD: D08QXD
 Compound Name LG100754 Investigative [55]
Synonyms
LG 100754; LG754
    Click to Show/Hide
External Link
CID: 6442223
TTD: D0Q9FZ
References
Ref 1 The Mechanism of Oxymatrine Targeting miR-27a-3p/PPAR-gamma Signaling Pathway through m6A Modification to Regulate the Influence on Hemangioma Stem Cells on Propranolol Resistance. Cancers (Basel). 2023 Oct 30;15(21):5213. doi: 10.3390/cancers15215213.
Ref 2 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. doi: 10.1038/nm784. Epub 2002 Oct 15.
Ref 3 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. doi: 10.1002/ijc.10980.
Ref 4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 5 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-Gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. doi: 10.1007/s40261-014-0197-y.
Ref 6 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. doi: 10.1074/jbc.275.22.16638.
Ref 7 A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
Ref 8 Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (Gamma) agonist. Mini Rev Med Chem. 2012 Feb;12(2):87-97. doi: 10.2174/138955712798995048.
Ref 9 Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84.
Ref 10 Clinical pipeline report, company report or official report of Minoryx Therapeutics
Ref 11 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. doi: 10.1177/0091270003257230.
Ref 12 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatography-tandem mass spectrometry. Pharmazie. 2007 Nov;62(11):825-9.
Ref 13 Tesaglitazar, a dual PPAR-Alpha/Gamma agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicol Pathol. 2012;40(1):18-32. doi: 10.1177/0192623311429972. Epub 2011 Nov 30.
Ref 14 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005 Aug;27(8):1181-95. doi: 10.1016/j.clinthera.2005.08.005.
Ref 15 Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARAlpha agonist with moderate PPARGamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. doi: 10.1007/s40261-013-0128-3.
Ref 16 A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. doi: 10.1016/j.ejphar.2004.05.020.
Ref 17 MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. doi: 10.1210/me.2008-0473. Epub 2009 Apr 23.
Ref 18 FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8. doi: 10.1016/j.metabol.2005.04.012.
Ref 19 Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84. doi: 10.1016/j.bone.2005.07.008. Epub 2005 Aug 30.
Ref 20 PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7. doi: 10.2174/13894501113149990162.
Ref 21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 22 Clinical pipeline report, company report or official report of Avarx.
Ref 23 The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. doi: 10.1124/dmd.106.012328. Epub 2006 Sep 29.
Ref 24 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 25 T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
Ref 26 Phrma report (2013 Alzheimers disease)
Ref 27 A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. doi: 10.1016/s0026-0495(03)00152-5.
Ref 28 Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/Gamma modulator, on adipogenesis and glucose metabolism in diabetic obese mice. Exp Clin Endocrinol Diabetes. 2015 Sep;123(8):492-9. doi: 10.1055/s-0035-1549965. Epub 2015 May 26.
Ref 29 PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61. doi: 10.1038/sj.ijo.802223.
Ref 30 Therapeutic potential of aleglitazar, a new dual PPAR-Alpha/Gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.
Ref 31 Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. doi: 10.1371/journal.pone.0038546. Epub 2012 Jun 7.
Ref 32 PPARGamma ligands and their therapeutic applications: a patent review (2008 - 2014). Expert Opin Ther Pat. 2015 Feb;25(2):175-91. doi: 10.1517/13543776.2014.985206. Epub 2014 Nov 21.
Ref 33 The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7. doi: 10.1254/jphs.fp0060360. Epub 2006 Aug 5.
Ref 34 [KRP-297, MCC-555]. Nihon Rinsho. 2001 Nov;59(11):2200-6.
Ref 35 DOI: 10.1038/scibx.2012.669
Ref 36 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. doi: 10.2174/092986611796378701.
Ref 37 Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30.
Ref 38 Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. doi: 10.1517/14728214.13.1.145.
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558)
Ref 40 Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci. 2008 Sep;108(1):40-8. doi: 10.1254/jphs.fp0072346. Epub 2008 Sep 6.
Ref 41 CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
Ref 42 New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. doi: 10.1517/13543784.17.8.1187.
Ref 43 PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004 Jul;24(1):18-23. doi: 10.1183/09031936.04.00098303.
Ref 44 Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato) oxovanadium(IV) in ZDF rats. Canadian Journal of Physiology and Pharmacology. 12/2003; 81(11):1049-55.
Ref 45 A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6. doi: 10.1179/135100002125000956.
Ref 46 The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 February; 30(2): 352-360.
Ref 47 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. doi: 10.1074/jbc.M401552200. Epub 2004 Jul 15.
Ref 48 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95. doi: 10.1210/endo.137.10.8828476.
Ref 49 Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
Ref 50 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 51 A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999 Nov 15;59(22):5671-3.
Ref 52 PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003 May;139(1):163-71. doi: 10.1038/sj.bjp.0705232.
Ref 53 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 54 CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
Ref 55 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.